Alnylam Pharmaceuticals (ALNY) PT Lowered to $125 at BMO Capital; Onpattro U.S. Approval Lacks Benefit From Cardiac Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 165.00 -9 (5.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $174.00 | 52 Week High | $109.10 | |||
| Open | $172.70 | 52 Week Low | $31.38 | |||
| Day High | $180.61 | P/E | N/A | |||
| Day Low | $163.30 | EPS | $-1.45 | |||
| Volume | 7,056,744 | |||||
